# US 2021/0267970 A1 · Methods of treating disease with levoketoconazole

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0267970 A1
- Document ID: US20210267970A1
- Status: Published application
- Kind: A1
- Application number: 17/319,781
- Filed: 2021-05-13
- Published: 2021-09-02
- Earliest claimed: 2019-03-04
- Assignees: Strongbridge Dublin Limited
- Applicants: Strongbridge Dublin Limited
- Inventors: Fredric COHEN
- Web page: https://patentgrep.com/patent/US20210267970A1

## CPC

- A61K 31/497: containing further heterocyclic rings
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 31/155: Amidines ([IMAGE cpc-sch-A61K-1029.gif]), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61P 5/46: for decreasing, blocking or antagonising the activity of glucocorticosteroids
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein is a method of administering levoketoconazole, or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the subject is also being administered a multidrug and toxin extrusion transporter 1 (MATE1) substrate or an organic cation transporter 2 (OCT2) substrate.

## Claims

### Claim at position 1

-28. (canceled)

### Claim 29

A method of treating Cushing's syndrome in a subject in need thereof, wherein the subject also has type 2 diabetes mellitus and is being co-administered metformin, or a pharmaceutically acceptable salt thereof, to improve glycemic control, comprising:
administering a therapeutically effective amount of levoketoconazole, or a pharmaceutically acceptable salt thereof, to the subject in need thereof, wherein the therapeutically effective amount of levoketoconazole, or a pharmaceutically acceptable salt thereof, is determined via a titration scheme,
during the levoketoconazole titration scheme, monitoring the subject for a dose limiting event wherein the dose limiting event is a decreased fasting glucose level, abnormal kidney function, and/or a low Vitamin B-12 level; and
if the subject experiences a dose limiting event, reducing the amount of metformin, or a pharmaceutically acceptable salt thereof, administered to the subject.

### Claim 30 (depends on 29)

The method of claim 29, wherein the Cushing's syndrome is caused by excessive secretion of adrenocorticotrophic hormone (ACTH).

### Claim 31 (depends on 30)

The method of claim 30, wherein the excessive secretion is caused by a pituitary corticotroph adenoma.

### Claim 32 (depends on 29)

The method of claim 29, wherein the subject has had previous surgery or radiation to treat the subject's Cushing syndrome.

### Claim 33 (depends on 29)

The method of claim 29, wherein the subject has not had previous surgery or radiation to treat the subject's Cushing syndrome.

### Claim 34 (depends on 29)

The method of claim 29, wherein reducing the amount of metformin, or a pharmaceutically acceptable salt thereof, comprises reducing the dose of the metformin, or a pharmaceutically acceptable salt thereof, and maintaining the frequency of administration of the metformin, or a pharmaceutically acceptable salt thereof.

### Claim 35 (depends on 34)

The method of claim 34, wherein the dose of the metformin, or a pharmaceutically acceptable salt thereof, is reduced by at least 25%.

### Claim 36 (depends on 34)

The method of claim 34, wherein the dose of the metformin, or a pharmaceutically acceptable salt thereof, is reduced by at least 50%.

### Claim 37 (depends on 29)

The method of claim 29, wherein reducing the amount of metformin, or a pharmaceutically acceptable salt thereof, comprises maintaining the dose of the metformin, or a pharmaceutically acceptable salt thereof, and reducing the frequency of administration of the metformin, or a pharmaceutically acceptable salt thereof.

### Claim 38 (depends on 29)

The method of claim 29, wherein the titration scheme comprises administering a first dose of the levoketoconazole, or a pharmaceutically acceptable salt thereof, for a first time period;
increasing the dose by an amount equal to an incremental value of 150 mg daily; and
determining whether the subject tolerates the increased dose;
wherein the cycle is repeated so long as the subject tolerates the increased dose, wherein the incremental value at each cycle repetition is the same or different; and
wherein if the subject does not tolerate the increased dose, the dose for the patient is equal to the difference between the further increased dose and the incremental value for the last cycle repetition.

### Claim 39 (depends on 38)

The method of claim 38, wherein the first dose of the levoketoconazole, or a pharmaceutically acceptable salt thereof, is 150 mg administered twice daily.

### Claim 40 (depends on 29)

The method of claim 29, wherein the therapeutically effective amount of the levoketoconazole, or a pharmaceutically acceptable salt thereof, is between 150 mg and 1200 mg per day.

### Claim 41 (depends on 29)

The method of claim 29, wherein the therapeutically effective amount of the levoketoconazole, or a pharmaceutically acceptable salt thereof, is 600 mg twice daily.

### Claim 42 (depends on 29)

The method of claim 29, further comprising informing the subject or a medical care worker that co-administration of the levoketoconazole, or a pharmaceutically acceptable salt thereof, and the metformin, or a pharmaceutically acceptable salt thereof, may result in increased exposure to metformin.

### Claim 43 (depends on 29)

The method of claim 29, further comprising informing the subject or a medical care worker that co-administration of the levoketoconazole, or a pharmaceutically acceptable salt thereof, and metformin, or a pharmaceutically acceptable salt thereof, may result in one or more exposure-related adverse reactions associated with metformin, or a pharmaceutically acceptable salt thereof.

### Claim 44 (depends on 29)

The method of claim 29, further comprising monitoring the subject for one or more exposure-related adverse reactions associated with metformin, or a pharmaceutically acceptable salt thereof.

### Claim 45 (depends on 44)

The method of claim 44, wherein the one or more exposure-related adverse reactions are chosen from diarrhea, nausea/vomiting, flatulence, asthenia, indigestion, abdominal discomfort, lactic acidosis, and headache.

### Claim 46 (depends on 29)

The method of claim 29, wherein the levoketoconazole, or a pharmaceutically acceptable salt thereof, is administered as a dosage form suitable for oral administration.

### Claim 47 (depends on 46)

The method of claim 46, wherein the dosage form is an immediate release tablet.

### Claim 48 (depends on 47)

The method of claim 47, wherein the tablet comprises one or more pharmaceutical excipients chosen from microcrystalline cellulose, lactose, corn starch, colloidal silicon dioxide, and magnesium stearate.
